Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Miaoyi Wu"'
Autor:
Xuechao Liu, Guangfeng Wang, Xianglei Yan, Haibo Qiu, Ping Min, Miaoyi Wu, Chunyang Tang, Fei Zhang, Qiuqiong Tang, Saijie Zhu, Miaozhen Qiu, Wei Zhuang, Douglas D. Fang, Zhiwei Zhou, Dajun Yang, Yifan Zhai
Publikováno v:
Cell & Bioscience, Vol 9, Iss 1, Pp 1-12 (2019)
Abstract Background Imatinib shows limited efficacy in patients with gastrointestinal stromal tumors (GISTs) carrying secondary KIT mutations. HQP1351, an orally bioavailable multikinase BCR-ABL inhibitor, is currently in clinical trials for the trea
Externí odkaz:
https://doaj.org/article/684f49e1df854ee8a1b2931e36258433
Autor:
Guangfeng Wang, Yifan Zhai, Ping Min, Miao Zhen Qiu, Chunyang Tang, Qiuqiong Tang, Douglas D. Fang, Xuechao Liu, Zhiwei Zhou, Xianglei Yan, Dajun Yang, Fei Zhang, Haibo Qiu, Wei Zhuang, Miaoyi Wu, Zhu Saijie
Publikováno v:
Cell & Bioscience, Vol 9, Iss 1, Pp 1-12 (2019)
Cell & Bioscience
Cell & Bioscience
Background Imatinib shows limited efficacy in patients with gastrointestinal stromal tumors (GISTs) carrying secondary KIT mutations. HQP1351, an orally bioavailable multikinase BCR-ABL inhibitor, is currently in clinical trials for the treatment of
Autor:
Suyan Tian, Xue Zhang, Xuejuan Sun, Feng Yan, Xuetong Zhu, Miaoyi Wu, Qiang Wang, Kewei Liu, Jinmei Wang, Jiancheng Xu
Publikováno v:
Journal of Public Health and Emergency. 5:4-4
Background: We aimed to describe the laboratory characteristics of patients with laboratory confirmed coronavirus disease 2019 (COVID-19), and to compare the laboratory data between recovered and non-recovered patients. Methods: This is a multi-cente
Autor:
Dingxiong Chen, Ran Tao, Fei Zhang, Rongcheng Xu, Guangfeng Wang, Jiajun Li, Li Rui, Shoulai Gu, Feifei Zhang, Miaoyi Wu, Yifan Zhai, Ping Min, Douglas D. Fang, Dajun Yang, Yingfeng Li, Kejie Lian, Lvcheng Wang, Chunyang Tang, Jingwen Wang
Publikováno v:
Cancer Research. 79:2204-2204
Focal adhesion kinase (FAK) plays an important role in cell migration, growth factor signaling, cell cycle progression and cellular survival. It had been shown that FAK and SRC family kinases were able to sustain downstream AKT and MAPK signaling und
Autor:
Shaomeng Wang, Ming Guo, Shuo Dang, Miaoyi Wu, Jing Deng, ChuanYan Tang, Yifan Zhai, Douglas D. Fang, Fei Zhang, Guangfeng Wang, Ping Min, Yang Dajun
Publikováno v:
Cancer Research. 78:307-307
Small cell lung cancer (SCLC) is one of the most deadly diseases with a dismal five year survival rate less than 7%. Even though most SCLC patients respond to the initial platinum-based cytotoxic or radiation therapies, they inevitably relapse and su
Autor:
Shuo Dang, Guangfeng Wang, Chunyang Yang, Douglas D. Fang, Yifan Zhai, Wei Zhuang, Miaoyi Wu, Fei Zhang, Dajun Yang, Zhiwei Zhou, Ping Min, Haibo Qiu
Publikováno v:
Cancer Research. 78:1979-1979
Gastrointestinal stromal tumors (GIST) harbor driver mutations of signal transduction kinases such as KIT. Besides surgical resection for primary localized tumors, imatinib remains the first-line treatment for advanced and metastatic GISTs. Imatinib